New hope for younger AML patients: targeted chemo combo shows promise

NCT ID NCT04269213

First seen Nov 14, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests a chemotherapy drug called CPX-351 in people under 60 who have a type of leukemia that developed from a previous blood disorder or cancer treatment. The goal is to see how well the drug can stop the cancer from growing and achieve remission. About 21 participants will receive the treatment, and researchers will track how long any remission lasts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Allegheny Health Network Cancer Institute - West Penn Hospital

    Pittsburgh, Pennsylvania, 15224, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • SUNY Upstate Medical Center

    Syracuse, New York, 13210, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

Conditions

Explore the condition pages connected to this study.